Visit | Screening −10 to −6 weeks | Run-ina −6 to 0 weeks | Randomisation 0 weeks | Follow-upb | |||
---|---|---|---|---|---|---|---|
3 monthly | 6 monthly | Annually | Finalc | ||||
Time window for evaluation | N/A | + 2 days | N/A | ±14 days | ±14 days | ±14 days | N/Ac |
Informed consent (prior to or at screening) | X | Â | Â | Â | Â | Â | Â |
Assessment of eligibility | X | Â | Â | Â | Â | Â | Â |
Demographics | X | Â | Â | Â | Â | Â | Â |
Anthropometrics—height and weight | X |  |  |  |  | Xf | Xf |
Behavioural—smoking | X |  |  |  |  |  |  |
Medical history | X | Â | Â | Â | Â | Â | Â |
Concomitant medications | X | Â | Â | Â | Â | X | X |
AAA imaging (standard care)h | X | Â | Â | Â | Â | X | X |
Blood tests—creatinine, eGFR, HbA1c, CRP (if available), LDL-C (if available)d | X |  |  |  |  | Xg | Xg |
Blood sample for biomarker sub-studye | X | Â | Â | Â | Â | Xe | X |
QoL questionnaires: SF-36, AneurysmDQoL | X | Â | Â | Â | Â | X | X |
Run-in medication dispensed | X | Â | Â | Â | Â | Â | Â |
Randomisation | Â | Â | X | Â | Â | Â | Â |
Study medication dispensed | Â | Â | X | Â | X | X | Â |
Study medication adherence | Â | X | Â | X | X | X | X |
AESI reporting | Â | X | Â | X | X | X | X |
Serious adverse event reporting | Â | X | Â | X | X | X | X |
Assessment of exploratory outcomes not classified as SAEs (diagnosis of cancer, diagnosis of diabetes, symptomatic gout) | Â | Â | Â | X | X | X | X |
Health economic assessment questions | Â | Â | Â | Â | Â | X | X |